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INTRODUCTION 
The ability to understand and counteract weightlessness-induced bone loss will be critical 
for crew health and safety during and after space station or exploration missions lasting months 
or years, respectively. Until its deorbit in 2001 , the Mir Space Station provided a valuable 
platform for long-duration space missions and life sciences research. Long-duration flights are 
critical for studying bone loss, as the 2- to 3-week Space Shuttle flights are not long enough to 
detect changes in bone mass. This review will describe human spaceflight data, focusing on 
biochemical surrogates of bone and calcium metabolism. This subject has been reviewed 
previously. 1-9 
BONE L OSS 
Bone mineral is lost during spaceflight because weightlessness unloads the skeleton. 10-17 
This has been known for decades, but determining predictive factors or showing changes that are 
consistent from subject to subject has proved difficult. 
When changes in bone density are caused by unloading, the changes in different skeletal 
regions do not necessarily correlate with the change in total body calcium or overall calcium loss. 
Oganov et al. 16 found mineral losses averaging 2.8, 8.2, 5.0, and 6.2% in the tibia, greater 
trochanter, _femoral neck, and lumbar v~rtebrae, respe?tiv~y, of 7 exercis~g cosmo~auts v:~o 
stayed on Mir for 4 to 6 months. These 7 crewmembers had no change in total body calcium. 
Both spaceflight and ground-based analog studies have shown that the loss of calcium from 
bones varies among sites within a subject, and that the nature and degree ofloss over time varies 
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between sUbjects. 12,14,17-20 
Virtually every astronaut on missions longer than 30 days has lost bone in some region. 
The constraints and difficulties of spaceflight research have prevented studies to date from 
finding any explanation for individual differences . 
Whether factors such as exercise (type, frequency, technique, etc.), diet, and environment 
playa role in this variability has yet to be determined. Such factors may be critical in finding 
countermeasures for bone loss of spaceflight, or conversely, they may influence the effectiveness 
of a countermeasure once it has been defmed. For instance, in the event that an exercise profile 
is defined that preserves bone during weightlessness, and a crewrnember is not consuming 
enough calcium, then the countermeasure may appear to have failed. Given the small number of 
crewmembers available for study, this might prove to be a significant hindrance to resolving the 
problem of bone loss. 
CALCIUM BALANCE AND CALCIUM METABOLISM 
Negative calcium balance was observed during Skylab ll ,2 1-23 and Mir4 mISSIOns. 
Increased urinary and fecal calcium excretion accounted for most of the deficit. li ,14,21-23 ,2S-27 
Increased calcium excretion is a major contributor to the increased risk of renal stone formation 
d~~_ 3?d after spa~ep~g~. 25-27 
Recent studies with calcium24 and strontium28 tracers have shown that the calcium 
absorption of crewrnembers decreased aboard the Mir space station. The calcium tracer studies 
included mathematical modeling of the calcium kinetics, which estimated a net bone calcium loss 
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of about 250 mg/d. 24 This fits very closely with the Skylab calcium balance data, which showed 
whole-body calcium losses of200 to 300 mg/d. l 
While early hypotheses suggested that space travelers' serum concentrations of total and 
ionized calcium would increase, only very small changes have been noted, and those have had 
only statistical rather than clinical significance.24,29 Thus, despite the bone loss and 
hypercalciuria associated with spaceflight, the body's regulation of circulating calcium levels 
remains intact. 
BONE METABOLISM AND BONE MARKERS 
As a living tissue, bone is constantly subject to remodeling through the processes of bone 
formation and bone resorption. The activity of these processes may be determined by a number 
of methods, ranging from extremely invasive (bone biopsy) to noninvasive (markers found in 
urine). The battery of biochemical markers available has evolved over the past 4 decades of 
humans flying in space. Although more sensitive and specific markers have recently become 
available, it is reassuring to find that the results of studies showing the effects of spaceflight on 
bone metabolism are very consistent, essentially regardless of technique. 
Bone formation is generally unchanged or decreased during spaceflight. Typically, blood 
which are bone-specific alkaline phosphatase (BSAP) and osteocalcin. Studies from a few 
astronauts and cosmonauts on Mir have yielded mixed results, but again, the general finding was 
that these markers were unchanged or decreased compared to their preflight serum 
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concentrations.24,30,31 ,32 Kinetic studies with calcium tracers yielded similar results for bone 
formation (i.e., it decreased in one crewmember and was unchanged in the other twO) ?4 In all of 
these studies, unfortunately, the number of subjects was very small. 
While bone formation may remain unchanged, or perhaps decrease slightly, during 
spaceflight, bone resorption clearly increases. Several biochemical markers in blood or urine 
samples reflect bone resorption activity. Increases in urinary calcium excretion, perhaps the 
oldest ofthe markers, are consistently observed during and soon after spaceflight. 10, 11 ,14,22·27 
During the Skylab 4 mission, calcium losses correlated roughly with calcaneal mineral losses 
determined by bone density studies.33 
Hydroxyproline in urine may be used as a marker of bone resorption. Posttranslational 
modifications of collagen form this amino acid, which appears in urine when collagen breaks 
down. As with all surrogates, hydroxyproline has its limitations. A key example: the metabolism 
of dietary collagen can also produce hydroxyproline. Nevertheless, the fmding that urinary 
hydroxyproline excretion was elevated 33% after the 84-d Skylab 4 flight23,34corroborates other 
evidence of bone resorption during spaceflight. 
The 1990s brought the ability to measure collagen crosslinks, a family of compounds that 
appear in the urine as a result of collagen degradation associated with bone resorption. Several 
crosslink fragments can be measured by high-performance liquid chromatography, and many by 
C?gun~!9}.~lly avai!a~le enzyrpe-linked irnrn~osor~~nt a~~ays. Frag:rp.e:gts <2fjpterest in~L~~ 
pyridinoline, deoxypyridinoline, N-telopeptide, and C-telopeptide. In general, all provide similar 
results. The advantages of using crosslinks include the fact that these compounds are formed 
only in mature collagen, and thus their release reflects breakdown of mature collagen; the 
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fragments are not absorbed from the gut, and thus dietary consmnption does not confound 
results; and these compounds are extremely stable in frozen urine samples for a long period. 
Data from spaceflight studies very consistently show increased levels of markers of bone 
resorption. 24,30,3 1,35,36 Calcium tracer kinetic data also indicated that bone resorption increased 
about 50% during flight. 24 
Because of the increasing use of collagen crosslinks as markers, a few comments are 
warranted about common perceptions and misconceptions. Critics of using collagen crosslinks 
often point out that they vary considerably from day to day and from subject to subject, and this 
criticism is well founded. However, the day-to-day variability may be minimized by extending 
the sample collection period, an action more easily accomplished in research than in clinical 
settings. With regard to the subject-to-subject variability, although this is indeed considerable, 
the response to intervention (e.g., spaceflight, bed rest, or exercise) is highly consistent between 
subj ects. For example, although the amount of a collagen crosslink excreted in 24 hours can 
easily vary 5- to la-fold between 2 subjects, if those same 2 subjects go into space, they will 
have the same magnitude of response compared to their preflight level. 
Another common issue is that of normalizing crosslink excretion to creatinine excretion. 
Whereas in a clinical setting the collection of individual urine voids may make this necessary, in 
research it should be avoided wherever possible. This is especially, and perhaps obviously, true 
One clear limitation of using these biochemical markers is that they reflect changes in the 
-
entire skeletal system, and regional differences may be missed or masked. Because of this, 
whenever possible the bone markers should be determined in conjunction with other tests (bone 
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I density measurements, for example), to ensure that multiple perspectives are considered. 
l However, the changes in spaceflight are clear enough to alleviate concerns about this potential 
I problem. 
ENDOCRINE EFFECTS 
In an attempt to define the mechanism of weightlessness-induced bone loss, many studies 
have focused on the endocrine regulation of bone and calcium metabolism. In general, changes 
in the endocrine regulation of bone metabolism seem to reflect adaptation to the weightless 
environment (that is, the system functions normally to decrease bone mass), 
The absence of ultraviolet light and decreased dietary intake of vitamin D during 
spaceflight diminish vitamin D pools in the body. This was observed during the 84-d Skylab 
rnission22 and the 115-d Mir rnission. 24 However, on Skylab, the slight decrease occurred despite 
dietary supplements of 500 IU of vitamin D/d.22 Crewmembers on the International Space 
Station are provided with vitamin D supplements, but this is done because of concerns about the 
amount of vitamin D provided by the food system. In other words, the supplements are intended 
to prevent a dietary deficiency, and are not expected to correct bone loss. 
Circulating parathyroid hormone concentrations decrease during flight, albeit with some 
variability.22,24,31,37 Decreased levels ofthe active form of vitamin D - 1,25-dihydroxyv:itamin D -
- - - - - - - - - - --
have been observed on long-duration flights,24 and these changes occurred much earlier than 
changes in the vitamin D stores. Parathyroid hormone is required for synthesis of 
1,25-dihydroxyvitamin D. Thus, the decreased concentration of 1,25-dihydroxyvitamin D 
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I observed during spaceflight seems to be related to decreased production secondary to decreased 
parathyroid hormone concentrations, rather than increased disposaL No changes in circulating 
vitamin D metabolites were observed on one Shuttle flight, but preflight concentrations varied 
considerably?? 
Changes in the endocrine regulation of bone metabolism seem to reflect adaptation to the 
weightless environment. Decreases in calcium absorption and blood levels of parathyroid 
hormone and 1,25-dihydroxyvitamin D are expected physiological responses to increased 
resorption of bone. Resorption is likely stimulated as the body adapts to an environment in 
which bones bear less weight. It is estimated, on the basis of limited available data, that recovery 
of the lost bone will take about 2 to 3 times the length of the mission.24 While more data clearly 
are required to validate tllls hypothesis, it has significant implications as mission durations 
increase. For planetary missions, the ability of a terrestrial partial g force (such as Mars' 0.38 g) 
to reduce bone loss, or even allow recovery to begin, is unknown. While no data exist on 
responses to partial g , the general consensus among investigators is that forces less than 0.5 g 
(for example, the Martian 0.38 g) are likely to be of little value to bone. 
DIETARY INFLVENCE 
Several nutrien_ts affect ~<:me a~d calcium homeostasis. rQe~e include cal~i!:lID-, v~t3.I!!in 
D, vitamin K, protein, sodium, and phosphorus. Supplemental calcium is an important adjunct in 
the treatment of patients with osteoporosis,38 but it does not correct the problem of bone loss 
during spaceflight. The importance of vitamin D was addressed earlier in this article. Vitamin K 
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is responsible for carboxylation reactions in osteocalcin synthesis. The importance of vitamin K 
during spaceflight has been addressed in preliminary reports,39 but the subj ect clearly requires 
further study. 
Dietary sodium during spaceflight is also a subj ect of concern, as it is known to affect 
calcium homeostasis.40-44 Dietary sodium also seems to exacerbate the calciuric responses to 
unloading: subjects consuming a low sodium diet (100 mmolld) had no change in urinary 
calcium, while those on a high sodium diet (190 mmolld) exhibited hypercalciuria.45 Space diets 
tend to have relatively high amounts of sodium, and increased dietary sodium is typically 
associated with hypercalciuria (as reviewed by Nordin et al. ,42 and Heer et a1.43). 
COUNTERMEASURE POTENTIAL 
The ability of many countermeasures to ameliorate spaceflight-induced bone loss has 
been tested. However, the countermeasured tested to date, including exercise, increased calcium 
and/or phosphate intake, vitamin D supplementation, exposure to ultraviolet light, and 
administration of early-generation bisphosphonates, have proved ineffective during spaceflight or 
bed rest. 5,46-49 Whether resistive exercise paradigms, newer anti-resorptive therapies, or other 
therapies involving bone-regulating proteins will prevent or reduce bone loss is yet to be 
determined. Ensuring adequate di~taryint~ke, Qri,n sQme c,!~es epsurillg adequate syntllel>is., of 
calcil!ll, vitamin D, vitamin K, and other bone-related nutrients will be necessary, but does not 
appear to be sufficient to solve the problem of bone loss. Other factors that may also contribute 
to the degree of calcium loss are age, gender, fitness , genetics, and dietary history. The 
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importance of these in preventing (or hastening) bone loss has yet to be determined. 
SUMMARY 
Spaceflight-induced bone loss poses significant health risks for astronauts, both acutely 
and chronically. Future research is required to better understand the nature ofthis bone loss, to 
define the time course of its effects, and to develop means to counteract it. Successful resolution 
of these tasks will increase crew safety during spaceflight, will enable human exploration 
missions, and may provi?e insight into the treatment of diseases on Earth. 
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